Kintor long term safety phase 3 Research/Science 3/21/2025
Kintor's phase III trial for pyri (KX-826) showed promising safety and efficacy results, with no drug-related sexual dysfunction reported. Users discussed their experiences with pyri, Minoxidil, Dutasteride, and concerns about the validity of the study results.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity Waiting to start treatment until Kintor KX-826 Phase 2 data is published?
People are waiting for KX-826 (Pyrilutamide) Phase 2 data to decide on hair loss treatments, with some considering finasteride or minoxidil in the meantime. Pyrilutamide is seen as a potentially stronger and safer alternative to finasteride, but concerns about side effects and availability remain.
community KX-826 Phase 3 Failed. Sorry guys...
The conversation discusses the failure of Phase 3 trials for the hair loss treatment KX-826, with no significant difference found between the drug and placebo. Some users express disappointment and skepticism, while others discuss alternative treatments like Minoxidil, finasteride, and RU58841.
community I interviewed Kintor: GT20029 Clinical Trial Pictures. As well as KX826.
GT20029 and KX826 are promising hair loss treatments, with GT20029 increasing hair count and KX826 showing significant results. KX826 may be a good alternative for those who can't use finasteride or dutasteride, though results vary.
community Target Area Hair Count (TAHC) increase comparasion of all future treatments in clinical trial phases
Finasteride, Minoxidil, Bioneer CosmeRNA, Technoderma, Kintor, Hope, Breezula, and Follicum treatments showed increases in hair count, with Technoderma showing the highest increase at 24.3 hairs/cm². Amplifica has not yet published results.
community Why do I have the feeling that this subreddit is flooded by Kintor employees?
Users discuss aggressive promotion of Koshine 826, suspecting Kintor employees are behind it. Concerns are raised about its effectiveness, with some preferring alternatives like finasteride and minoxidil.
Related Research
6 / 6 results
research Androgen receptor modulators: a review of recent patents and reports (2012-2018)
This review discusses AR-modulating agents developed between 2012 and 2018, highlighting challenges with ligand-binding domain antagonists and proposing nonconventional approaches targeting other domains as promising strategies.
research Hair Supplements
This review discusses commonly used dietary supplements for hair growth and highlights the lack of evidence supporting their efficacy and safety in the absence of nutritional deficiency; it reports no new research results.
research 5% Minoxidil: treatment for female pattern hair loss.
Recent Phase III trials reported that once daily 5% minoxidil foam significantly increased hair count in women with female pattern hair loss and was shown to be as effective as twice daily 2% minoxidil solution.
research Insight into Recent Advances in Degrading Androgen Receptor for Castration-Resistant Prostate Cancer
This review highlights recent progress in developing androgen receptor degraders, such as PROTACs, for treating castration-resistant prostate cancer, and notes that several have entered phase I or II clinical trials, showcasing potential to address drug resistance challenges.
research Proteolysis‐Targeting Chimera (PROTAC): Current Applications and Future Directions
This review discusses the development and clinical progression of PROTAC technology for targeted protein degradation, highlighting its potential to address previously "undruggable" targets but reports no new clinical results.
research PROTACs in 2025: from the laboratory concept to clinical breakthrough
This article discusses the impact of PROTACs technology in transforming drug discovery with its novel degradation mechanism, but it reports no new experimental findings.